In Situ Hybridization - Market Insights, Competitive Landscape, and Market Forecast - 2032

In Situ Hybridization Market by Product Type (Instruments, Reagents & Kits, and Software), Technology (Fluorescence In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH), and Others), Application (Cancer Diagnosis, Genetic Diseases, Infectious Diseases, and Others), End-User (Hospitals and Clinics, Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of cancer and genetic diseases and increasing incidences of neurological disorders and infectious disease

The in situ hybridization market was valued at USD 1,673.55 million in 2024, growing at a CAGR of 7.12% during the forecast period from 2025 to 2032 to reach USD 2,886.13 million by 2032. The demand for in situ hybridization is witnessing a notable surge, driven predominantly by the escalating prevalence of cancer and genetic diseases. Additionally, the upward trend in neurological disorders and infectious diseases further fuels this demand. Coupled with this, the intensifying R&D activities and funding are pivotal factors propelling the positive growth trajectory of the in situ hybridization market. This growth trend is expected to persist and flourish throughout the forecast period spanning from 2025 to 2032.

In Situ Hybridization Market Dynamics:

ISH is used to diagnose congenital diseases such as Down's syndrome and Edward's Syndrome. It enables researchers to analyze how certain genes are expressed in tissues or organs, shedding light on their involvement in developmental processes, diseases, and physiological functions. Therefore, the rising number of people affected by genetic or some kind of rare disease is expected to contribute to the growth of the market. For instance, a report by the World Economic Forum in February 2023, stated that approximately 475 million individuals were suffering from rare conditions in 2019 which comprised 10% of the global population. Within the upcoming five years, it was anticipated that around 15.2 million people were expected to undergo clinical genomic testing specifically aimed at identifying rare conditions.

According to an article shared by Johnson & Johnson in February 2023, the estimate suggests that over 300 million individuals were affected with rare diseases as of 2023 globally. Fluorescence in situ hybridization (FISH) is a genetic testing technique used by pathologists to aid in diagnosing diseases attributed to chromosomal abnormalities. Therefore, the growing genetic and rare diseases contribute to the extensive use of in situ hybridization which is expected to drive the market growth.

According to data cited by the World Health Organization in 2022, around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020 around the world.

As per data published by Global Cancer Observatory in 2021, around 544,352 cases of non-Hodgkin lymphoma and 83,087 cases of Hodgkin lymphoma were reported in 2020 worldwide. As per the same source, around 474,519 leukemia cases and nearly 176,404 cases of multiple myeloma were reported in 2020 across the globe. In situ hybridization serves as a valuable tool in examining changes in gene expression or chromosomal irregularities linked to cancer, aiding in the discovery of potential diagnostic indicators and targets for therapeutic intervention, thereby driving market growth.

The rising cases of infectious diseases such as HIV, hepatitis, and others is another key driver for the in situ hybridization (ISH) market. In situ hybridization (ISH) amalgamates laboratory medicine with molecular genetics technology to detect infectious pathogens. Fluorescence in situ hybridization (FISH) specifically aids in identifying and pinpointing nucleotide sequences within diverse samples, all while maintaining the integrity of cellular structures. According to the World Health Organization (WHO) 2022, it was estimated that around 354 million people were living with Hepatitis B or C infections in 2022 globally.

Government support and funding are directed towards maximizing the value derived from the Rare Diseases Partnership, with the overarching goal of fostering increased levels of research and innovation in the field of rare diseases. For instance, in September 2023, UK Research and Innovation, the investment, totaling nearly USD 798.5 million (GBP 627 million), encompasses various initiatives aimed at advancing rare disease research. Notably, USD 126.9 million (GBP 99.7 million) had been allocated to MRC fellowships and NIHR career development awards between 2016 and 2021, illustrating the comprehensive support network surrounding rare disease research efforts.

However, the in situ hybridization market may face growth constraints due to various factors, including the inefficiency of detecting DNA level rearrangements and chromosome pairs and concerns regarding potential exposure to radioactivity.

In Situ Hybridization Market Segment Analysis:

In Situ Hybridization Market by Product Type (Instruments, Reagents & Kits, and Software), Technology (Fluorescence In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH), and Others), Application (Cancer Diagnosis, Genetic Diseases, Infectious Diseases, and Others), End-User (Hospitals and Clinics, Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the technology segment of the in situ hybridization market, the fluorescence in situ hybridization (FISH) category is estimated to account for a significant revenue share in the in situ hybridization market in 2024. This is attributed to the growing use of FISH in cancer diagnosis and research. In oncology, FISH is utilized to identify genetic changes linked with cancer, including gene amplifications, deletions, and rearrangements of chromosomes. Fluorescence in situ hybridization (FISH) is mainly used in the diagnosis, categorization, prognosis, and anticipation of treatment outcomes in cancer patients.

The application of FISH spans a broad spectrum of scientific disciplines, including genetic counseling, subcellular studies, detection and localization of chromosome mutations, species identification, biomedical research, clinical diagnosis, toxicology, chromosomal biology, and comparative genomics.

Key players in the market are developing innovative kits and reagents for fluorescence in situ hybridization (FISH) procedures. For instance, in December 2021, BioGenex, a US-based molecular pathology company launched NanoVIP. NanoVIP is a compact, fully automated bench-top system equipped with visualization kits designed for fluorescence in situ hybridization (FISH) and in-situ hybridization (ISH). Its 10-slide design ensures reliability through automation, featuring eXACT(TM) temperature control modules for individual slide positions, precise management of reaction times, and liquid level sensors for accurate liquid handling. This meticulous control ensures the delivery of clean, intense, reliable, and reproducible stains, minimizing the need for repeat procedures.

Further, in cellular biology and neuroscience, scientists utilize techniques such as fluorescence in situ hybridization (FISH) to investigate the expression, localization, and dynamics of genes within cells and tissues. This method allows for the visualization of specific genes or RNA molecules in various cell types including neuronal cells, glial cells, and others. By studying gene expression patterns and their spatial distribution, researchers gain valuable insights into brain function, development, and the underlying mechanisms of neurological disorders. Additionally, FISH can aid in the diagnosis of genetic disorders by enabling the visualization of specific chromosomal regions or genes associated with these conditions. Therefore, the wide applications of the fluorescence in situ hybridization (FISH) category is expected to contribute to the growth of the segment, thereby driving the growth of the in situ hybridization market during the forecast period.

North America is expected to dominate the Overall In-Situ Hybridization Market:

North America is estimated to dominate the in situ hybridization market in 2024. This is attributed to the growing prevalence of cancer and rare genetic diseases. In situ hybridization (ISH) stands as a pivotal tool in cancer research and diagnosis, facilitating the detection of gene expression and genetic abnormalities linked with cancer. These capabilities significantly contribute to the growth of the market in the region. Moreover, the escalating number of molecular diagnostics tests conducted in the region further propels the expansion of the North America in situ hybridization market.

Fluorescence in situ hybridization (FISH) is a diagnostic test that maps the genetic material within human cells, pinpointing specific genes or gene segments. Due to its capability to detect genetic abnormalities linked to cancer, FISH serves as a valuable tool in diagnosing certain types of the disease. For instance, according to the National Cancer Institute 2020, it was estimated that around 1,806,590 cancer cases were diagnosed in the year 2020 in the United States.

According to the Centers for Disease Control and Prevention (CDC) in May 2024, approximately 5,700 babies were born with Down syndrome each year in the United States. This equates to a prevalence of about 1 in every 640 babies. In situ hybridization is used to identify an extra chromosome or an extra piece of a chromosome for diagnosis of Down syndrome. Therefore, the growing prevalence of rare and genetic diseases is expected to drive the market growth in the region.

In Situ Hybridization Market Key Players:

Some of the key market players operating in the in situ hybridization market include Abbott Laboratories, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., PerkinElmer Inc., Sysmex Corporation, Biocare Medical, LLC, Genemed Biotechnologies, Inc., NeoGenomics Laboratories, Advanced Cell Diagnostics, Inc., BioView, Bio-Rad Laboratories, Inc., Bio-Techne, QIAGEN, BioGenex, ZYTOVISION GmbH, Promega Corporation, Illumina, Inc., Danaher Corporation, and others.

Recent Developmental Activities in the In-Situ Hybridization Market:

• In January 2024, Biocare Medical, LLC, a US-based tissue diagnostic company announced its collaboration with Molecular Instruments to develop automated bioimaging. This partnership combines Biocare Medical's proficiency in automated bioimaging systems with MI's array of advanced HCR(TM) Products, establishing a new benchmark in automated in situ hybridization (ISH) and immunohistochemistry (IHC).
• In May 2023, Bio-Techne, a US-based life sciences company launched Advanced Cell Diagnostics (ACD)-branded RNAscope(TM) in situ hybridization (ISH). RNAscope HiPlex12 Flex Kit allows for the visualization of highly multiplexed RNA biomarkers utilizing the Hyperion XTi or previous versions of the Hyperion Imaging System. This cutting-edge system facilitates the simultaneous detection and precise quantification of over 40 biomarkers from any tissue sample in a single imaging step, employing Imaging Mass Cytometry.
• In November 2022, Biocare Medical, LLC completed the acquisition of Empire Genomics, a molecular biomarkers company pioneering in cancer research and diagnostics. This acquisition serves to complement our extensive portfolio of IHC antibodies, comprehensive molecular menu, and sophisticated automation platform.
• In January 2022, Bio-Techne announced its partnership with Akoya Biosciences, Inc. to develop a single-cell, spatial multiomics workflow for comprehensive, unbiased analysis of tissue samples. Through this agreement, both companies worked to develop an automated spatial multiomics workflow capable of conducting rapid, in situ analysis of multiple analytes at single-cell resolution across entire slides.

Key Takeaways from the In Situ Hybridization Market Report Study

• Market size analysis for current In Situ Hybridization Market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global In Situ Hybridization market.
• Various opportunities available for the other competitors in the In Situ Hybridization Market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current In Situ Hybridization market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for In Situ Hybridization market growth in the coming future?

TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS IN SITU HYBRIDIZATION MARKET REPORT STUDY

• In Situ Hybridization product providers
• Research organizations and consulting companies
• In Situ Hybridization related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in In Situ Hybridization
• Various end-users who want to know more about the In Situ Hybridization Market and the latest technological developments in the In Situ Hybridization Market.

FREQUENTLY ASKED QUESTIONS FOR THE IN SITU HYBRIDIZATION MARKET:

1. What is In Situ Hybridization?

• In situ hybridization (ISH) is a method in molecular biology utilized to identify and pinpoint specific nucleic acid sequences within fixed tissues, cells, or organisms. It involves pairing a labelled nucleic acid probe, complementary to the target sequence, with the sample. This probe, often tagged with a fluorescent dye, radioactive label, or another identifiable marker, binds to its complementary sequence in the sample. Following hybridization, the location of the probe within the sample is observed using microscopy or autoradiography, offering insights into the spatial arrangement of RNA or DNA molecules and facilitating the examination of gene expression patterns, chromosomal structure, and cellular interactions.

2. What is the market for In Situ Hybridization?

• The in situ hybridization market was valued at USD 1,673.55 million in 2024, growing at a CAGR of 7.12% during the forecast period from 2025 to 2032 to reach USD 2,886.13 million by 2032.

3. What are the drivers for the In Situ Hybridization market?

• The in situ hybridization market is slated to witness prosperity owing to factors such as the escalating prevalence of cancer and genetic diseases. Additionally, the upward trend in neurological disorders and infectious diseases further fuels this demand. Coupled with this, the intensifying R&D activities and funding are pivotal factors propelling the positive growth trajectory of the in situ hybridization market. This growth trend is expected to persist and flourish throughout the forecast period spanning from 2025 to 2032.

4. Who are the key players operating in the In Situ Hybridization market?)

• Some of the key market players operating in the in situ hybridization market include Abbott Laboratories, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., PerkinElmer Inc., Sysmex Corporation, Biocare Medical, LLC, Genemed Biotechnologies, Inc., NeoGenomics Laboratories, Advanced Cell Diagnostics, Inc., BioView, Bio-Rad Laboratories, Inc., Bio-Techne, QIAGEN, BioGenex, ZYTOVISION GmbH, Promega Corporation, Illumina, Inc., Danaher Corporation, and others.

5. Which region has the highest share in the In Situ Hybridization market?

• North America is estimated to dominate in the in situ hybridization market in 2024. This is attributed to the growing prevalence of cancer and rare genetic diseases. In situ hybridization (ISH) stands as a pivotal tool in cancer research and diagnosis, facilitating the detection of gene expression and genetic abnormalities linked with cancer. These capabilities significantly contribute to the growth of the market in the region. Moreover, the escalating number of molecular diagnostics tests conducted in the area further propels the expansion of the North America in situ hybridization market.